Heart Failure
Conditions
Interventions
Experimental group :In addition to the routine treatment for heart failure, NAD+ for injection was added. Each time, 50mg of coenzyme I was prepared with 50 ml of saline, and administered by intraveno
Control group:In addition to the routine treatment for heart failure, 50ml of saline was added and administered by intravenous drip. The infusion time was about 30-45 minutes, once per day, and the du
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 97 Years
Inclusion criteria
Inclusion criteria: (1) Age = 18 years old; (2) Patients who meet the diagnostic criteria for heart failure and are diagnosed as heart failure (NYHA II-IV), with reduced Ejection fraction (LVEF = 40%) or NT proBNP = 600 pg/mL; (3) Voluntarily participate in this study and provide a signed and dated written informed consent form in accordance with Good Clinical Practice and local laws before being included in clinical trials.
Exclusion criteria
Exclusion criteria: (1) Patients with high atrioventricular block, constrictive Pericarditis, obstructive cardiomyopathy or acute myocardial infarction; Complicated with malignant arrhythmia, Pulmonary embolism and other diseases; (2) Pregnant or recently pregnant women, lactating women; (3) Patients with various tumors and heart failure caused by taking anti-tumor drugs; (4) Coenzyme I, lactose intolerance or lactose allergy; (5) Secondary or primary unconsciousness, cognitive impairment, or abnormal mental behavior; (6) Individuals with a history of severe allergies or infusion reactions in the past; (7) Patients with severe liver and kidney dysfunction: ALT or AST>5 times the upper limit, glomerular filtration rate = 30mL/min/1.73 ?; (8) Engaging in clinical research on other drugs; (9) In addition to the above, the researchers have determined that there are other reasons why it is not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NT-proBNP; | — |
Secondary
| Measure | Time frame |
|---|---|
| LVEF;Left ventricular long axis strain;Cardiac function grading;rehospitalization;Cardiovascular event incidence rate; | — |
Countries
China
Contacts
Public ContactWang Fang
Beijing Hospital
Outcome results
None listed